Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Teluca
Basking Ridge, New Jersey, United Statesteluca.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Teluca is a clinical-stage biotechnology company specializing in the development of targeted radiopharmaceuticals for the treatment of hard-to-treat cancers. The company's lead program, TL-001, is a radiolabeled amino acid analog targeting the L-type amino acid transporter 1 (LAT1), currently being evaluated in Phase 1/2 clinical trials for glioblastoma multiforme. Teluca leverages its expertise in radiochemistry and oncology to create precision medicines that deliver therapeutic radiation directly to tumor cells while sparing healthy tissue. The company is headquartered in New Jersey and was founded by industry veterans with extensive experience in the radiopharmaceutical sector.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Teluca.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Teluca.